CVD	cardiovascular disease
HRT	hormone replacement therapy
TRT	testosterone replacement therapy
CV	cardiovascular
HF	heart failure
VTE	venous thromboembolism
LOH	late-onset hypogonadism
HpEF	heart failure with preserved ejection fraction
HIV	human immunodeficiency virus
EAU	European Association of Urology
SHBG	sex hormone-binding globulin
CAD	coronary artery disease
TT	total testosterone concentration
fT	free testosterone
MI	myocardial infarction
HDL	high-density lipoprotein
MACE	major adverse cardiovascular event
TOM	The Testosterone in Older Men with Mobility Limitations
DHEA	dehydroepiandrosterone
TC	total cholesterol
LDL	Low-density lipoprotein
TG	triglyceride
HbA1c	hemoglobin A1c
FPG	fasting plasma glucose
BP	blood pressure
6MWT	6-minute walk test
peak VO2	peak oxygen consumption
NYHA	New York Heart Association
AAS	anabolic androgenic steroid
LV	left ventricle
RAAS	renin–angiotensin–aldosterone system
EF	ejection fraction
RV	right ventricle
CCTA	coronary computed tomography angiography
FSH	follicle-stimulating hormone
LH	luteinizing hormone
DM	diabetes
WHI	Woman’s Health Initiative
USA	the United States
HR	hazard ratio
CI	confidence interval
NO	nitric oxide
ELITE	Early Versus Late Intervention Trial With Estradiol
CIMT	carotid artery intima-media thickness
ASCVD	atherosclerotic cardiovascular disease
TIA	transient ischemic attack
PE	pulmonary embolism
GAHT	gender-affirming hormone therapy
OR	odds ratio
SMR	standardized mortality ratio
COC	combined oral contraception
RR	relative risk
T2DM	type 2 diabetes
T1DM	type 1 diabetes
LVEF	left ventricular ejection fraction
POC	progestogen-only contraception
LG-IUDs	intrauterine levonorgestrel devices
IUDs	intrauterine devices
U.S. MEC	U.S. Medical Eligibility Criteria for Contraceptive Use
ACOG	American College of Obstetricians and Gynecologists